Jump to content

KEYNOTE-867 Study


Recommended Posts

Visit  https://merckoncologyclinicaltrials.com/en-us/patient/trial/NCT03924869 or call 888-577-8839 for more info

KEYNOTE-867 - Efficacy and safety study of stereotactic body radiotherapy (SBRT) with or without Pembrolizumab in adults with unresected stage I or II non-small cell lung cancer (NSCLC). (NCT03924869)

You may be able to join this study if:

·         You are at least 18 years of age.

·         You have been diagnosed with Stage I or IIA NSCLC that has not been treated.

·         You will undergo SBRT to treat your lung cancer instead of having surgery to remove the lung cancer.

·         You may require SBRT instead of surgery because:

o   You have other medical conditions that may prevent you from safely having surgery.

o   Your cancer is in a position that is difficult or not safe to operate on.

o   After being informed by the study doctor that surgery is the preferred treatment for your stage of lung cancer, you have decided not to have surgery

You have an equal (50/50) chance of being placed into one of the following groups:

Group A - SBRT and pembrolizumab

Group B - SBRT and placebo

You, your trial doctor, and the trial staff won’t know what drug you are getting. In case of a health emergency, they can find out.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.